Hosted on MSN19d
Today I Learned: How an Ilonggo Doctor Discovered Erythromycin
Eli Lilly eventually responded ... Flavier succinctly put it: "Dr Aguilar has contributed so much in the discovery of erythromycin. It is sad to hear that he got nothing out of it." ...
esquiremag20d
Today I Learned: How an Ilonggo Doctor Discovered Erythromycin
Aguilar, who used to work as a medical representative for the U.S. pharmaceutical firm, Eli Lilly and Company. The Origins of Erythromycin In 1949, Dr. Aguilar discovered the antibacterial properties ...
Pharmaceutical Technology24d
Danish biotech Orbis secures $94m to develop oral versions of biologics
The financing was led by New Enterprise Associates (NEA) with participation from new investors, including Eli Lilly, Cormorant ... as the immunosuppressant cyclosporine and the antibiotic erythromycin ...
Nature14d
The new antibiotics
Polyketides (e.g., erythromycin) are complex organic molecules ... In 1997, Cubist Pharmaceuticals (Cambridge, MA) also licensed from Eli Lilly (Indianapolis) daptomycin, a cyclic 13–amino ...
Eli Lilly Stock's Correction Brings Opportunity
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
Business Insider3d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...
The Motley Fool5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Business Insider3d
Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...
Yahoo Finance7d
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3% ...
Yahoo Finance12d
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50
Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...